Drug intelligence / Profile preview

AT-2001

Development stage: Preclinical
Lead developer: Eledon Pharmaceuticals

Overview

AT-2001 is a preclinical drug candidate that was acquired by Eledon Pharmaceuticals (then known as Novus Therapeutics) in September 2020 through its acquisition of Anelixis Therapeutics. Eledon Pharmaceuticals is developing AT-2001 for potential therapeutic applications in autoimmune diseases, transplantation, and neurodegenerative diseases.

Targets

CD40LG (CD40 ligand extracellular domain)

Beyond the preview

Go deeper on AT-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-2001.

Explore the full profile